132 related articles for article (PubMed ID: 38350157)
1.
Bajpai V; Tiwari S; Mishra A; Sure R; Sarode R; Bharti S; Pandey H; Kapoor A
Microb Drug Resist; 2024 Apr; 30(4):147-152. PubMed ID: 38350157
[No Abstract] [Full Text] [Related]
2. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital.
Bakthavatchalam YD; Shankar A; Muniyasamy R; Peter JV; Marcus Z; Triplicane Dwarakanathan H; Gunasekaran K; Iyadurai R; Veeraraghavan B
J Antimicrob Chemother; 2020 Aug; 75(8):2156-2159. PubMed ID: 32361727
[TBL] [Abstract][Full Text] [Related]
3. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.
Tellis M; Joseph J; Khande H; Bhagwat S; Patel M
J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18.
Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Dhole T; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Joshi P; Khande H; Mane A; Jain R; Bhagwat S
J Antimicrob Chemother; 2020 Mar; 75(3):600-608. PubMed ID: 31840170
[TBL] [Abstract][Full Text] [Related]
5. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay.
Baliga S; Mamtora DK; Gupta V; Shanmugam P; Biswas S; Mukherjee DN; Shenoy S
Indian J Med Microbiol; 2020; 38(3 & 4):307-312. PubMed ID: 33154240
[TBL] [Abstract][Full Text] [Related]
6. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA.
Saxena D; Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952
[TBL] [Abstract][Full Text] [Related]
7. Levonadifloxacin (WCK 771) exerts potent intracellular activity against
Dubois J; Dubois M
J Med Microbiol; 2019 Dec; 68(12):1716-1722. PubMed ID: 31689174
[No Abstract] [Full Text] [Related]
8. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
9. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
Bhagwat SS; Nandanwar M; Kansagara A; Patel A; Takalkar S; Chavan R; Periasamy H; Yeole R; Deshpande PK; Bhavsar S; Bhatia A; Ahdal J; Jain R; Patel M
Drug Des Devel Ther; 2019; 13():4351-4365. PubMed ID: 31920285
[TBL] [Abstract][Full Text] [Related]
10. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care.
Veeraraghavan B; Bakthavatchalam YD; Manesh A; Lal B; Swaminathan S; Ansari A; Subbareddy K; Rangappa P; Choudhuri AH; Nagvekar V; Mehta Y; Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Turbadkar D; Taklikar S;
Indian J Med Microbiol; 2023; 41():71-80. PubMed ID: 36509611
[TBL] [Abstract][Full Text] [Related]
11. Preclinical safety evaluation of levonadifloxacin, a novel anti-methicillin-resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration.
Nandanwar M; Kansagara A; Gupta S; Patel A; Patel MA; Yeole R; Thorve D; Patel M
J Appl Toxicol; 2022 Aug; 42(8):1354-1370. PubMed ID: 35146781
[TBL] [Abstract][Full Text] [Related]
12. Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral).
Saseedharan S; Dubey D; Singh RK; Zirpe K; Choudhuri AH; Mukherjee DN; Gupta N; Sahasrabudhe S; Soni S; Kulkarni S; Walse P; Vora AC; Thomas J; Tayade A; Bhadarke G; Kishore K; Paliwal Y; Patil P; Reddy PK; Nagvekar V; Veeraraghavan B
Indian J Med Microbiol; 2024; 47():100528. PubMed ID: 38228227
[TBL] [Abstract][Full Text] [Related]
13. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
14. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital.
Mamtora D; Saseedharan S; Rampal R; Joshi P; Bhalekar P; Ahdal J; Jain R
J Lab Physicians; 2020 Dec; 12(3):230-232. PubMed ID: 33268943
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD
J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837
[TBL] [Abstract][Full Text] [Related]
16. Assessment of
Chavan R; Zope V; Chavan N; Shaikh J; Patil K; Yeole R; Bhagwat S; Patel M
Xenobiotica; 2020 Oct; 50(10):1149-1157. PubMed ID: 32283993
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Morfin-Otero R; Noriega ER; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
20. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant
Bakthavatchalam YD; Rao SV; Isaac B; Manesh A; Nambi S; Swaminathan S; Nagvekar V; Nangia V; John PV; Veeraraghavan B
Indian J Med Microbiol; 2019; 37(4):478-487. PubMed ID: 32436868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
